GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Other Current Assets

Faron Pharmaceuticals Oy (LSE:FARN) Other Current Assets : £1.55 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Other Current Assets?

Faron Pharmaceuticals Oy's other current assets for the quarter that ended in Dec. 2023 was £1.55 Mil.

Faron Pharmaceuticals Oy's quarterly other current assets declined from Dec. 2022 (£2.09 Mil) to Jun. 2023 (£0.00 Mil) but then increased from Jun. 2023 (£0.00 Mil) to Dec. 2023 (£1.55Mil).

Faron Pharmaceuticals Oy's annual other current assets declined from Dec. 2021 (£3.34 Mil) to Dec. 2022 (£2.09 Mil) declined from Dec. 2022 (£2.09 Mil) to Dec. 2023 (£1.55 Mil).


Faron Pharmaceuticals Oy Other Current Assets Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Other Current Assets Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.01 1.89 3.34 2.09 1.55

Faron Pharmaceuticals Oy Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.34 - 2.09 - 1.55

Faron Pharmaceuticals Oy Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Faron Pharmaceuticals Oy Other Current Assets Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Traded in Other Exchanges
Address
Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines